Alkermes plc

Equities

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
27.25 USD +1.76% Intraday chart for Alkermes plc -1.66% -1.77%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Alkermes Insider Sold Shares Worth $292,740, According to a Recent SEC Filing MT
Baird Initiates Alkermes With Outperform Rating, Price Target is $37 MT
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors CI
European Equities Traded in the US as American Depositary Receipts Advance Wednesday MT
Alkermes Shares Down After Downgrade From UBS MT
UBS Downgrades Alkermes to Sell From Neutral, Price Target is $25 MT
Piper Sandler Raises Price Target on Alkermes to $39 From $32.54, Maintains Overweight Rating MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Sector Update: Health Care Stocks Higher Thursday Afternoon MT
Alkermes Shares Rise After Q4 Results, Guidance MT
Transcript : Alkermes plc, Q4 2023 Earnings Call, Feb 15, 2024
Alkermes Q4 Non-GAAP Earnings, Revenue Increase; 2024 Outlook Issued -- Shares Gain Pre-Bell MT
Earnings Flash (ALKS) ALKERMES Posts Q4 Revenue $377.5M, vs. Street Est of $362.4M MT
Alkermes plc announces an Equity Buyback for $400 million worth of its shares. CI
Alkermes plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Alkermes plc Provides Earnings Guidance for the Year 2024 CI
Alkermes plc authorizes a Buyback Plan. CI
Alkermes plc Announces Executive Changes CI
Transcript : Alkermes plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM
Alkermes plc Announces Topline Results from Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI CI
Alkermes plc(NasdaqGS:ALKS) added to S&P 1000 CI
Alkermes plc(NasdaqGS:ALKS) added to S&P 600 Health Care CI
Alkermes plc(NasdaqGS:ALKS) added to S&P Composite 1500 CI
Alkermes plc(NasdaqGS:ALKS) added to S&P 600 CI
Alkermes to Sell Ireland Facility to Novo Nordisk MT
Chart Alkermes plc
More charts
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
13
Last Close Price
27.25 USD
Average target price
34.83 USD
Spread / Average Target
+27.83%
Consensus
  1. Stock
  2. Equities
  3. Stock Alkermes plc - Nasdaq
  4. News Alkermes plc
  5. Sector Update: Health Care Stocks Finish With Small Gains